We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The number of regulatory breaches at drug manufacturing sites in India and China raises concerns about the fragility of the global supply chain, says a report by The Pharmaceutical Journal